Results 31 to 40 of about 2,455 (143)

Derivation and Validation of a Phenoconversion-Related Pattern in Idiopathic Rapid Eye Movement Behavior Disorder [PDF]

, 2023
Background: Idiopathic rapid eye movement sleep behavior disorder (iRBD) represents the prodromal stage of α-synucleinopathies. Reliable biomarkers are needed to predict phenoconversion.
Liguori C., Pardini M., Arnaldi D., Mattioli P., Giorgetti L., Donniaquio A., Meles S. K., Massa F., Nobili F., Bauckneht M., Orso B., Vallez Garcia D., Placidi F., Schillaci O., Morbelli S., Chiaravalloti A., Izzi F., Spanetta M., Giberti A., Leenders K. L., Mercuri N. B., Fama F., Camedda R.   +22 more
core   +3 more sources

CYP450 Genotype—Phenotype Concordance Using the Geneva Micrococktail in a Clinical Setting

Frontiers in Pharmacology, 2021
Pharmacokinetic variability is a major source of differences in drug response and can be due to genetic variants and/or drug-drug interactions. Cytochromes P450 are among the most studied enzymes from a pharmacokinetic point of view.
Kuntheavy Ing Lorenzini, Jules Desmeules, Victoria Rollason, Stéphane Bertin, Marie Besson, Youssef Daali, Caroline F. Samer   +6 more
doaj   +1 more source

Case Report: Performing a Medication Safety Review Assisted by Pharmacogenomics to Explain a Prescribing Cascade Resulting in a Patient Fall

Medicina, 2023
Pharmacotherapy for major depressive disorder (MDD) typically consists of trial-and-error and clinician preference approaches, where patients often fail one or more antidepressants before finding an optimal regimen.
Joshua Russell, Meghan J. Arwood, Nicole M. Del Toro-Pagán, Nishita S. Amin, Michele D. Cambridge, Jacques Turgeon, Veronique Michaud   +6 more
doaj   +1 more source

Evaluation of changes in cytochrome P450 2C19 activity in type 2 diabetic rats before and after treatment, by using isolated perfused liver model [PDF]

Iranian Journal of Basic Medical Sciences, 2020
Objective(s): Alteration in drug metabolism is very likely in diabetes mellitus. This study assessed changes in CYP2C19 enzymatic activity in the liver using omeprazole as a probe in the animal model of type II diabetes (T2DM) before and after treatment ...
Navid Neyshaburinezhad, Mohammad Reza Rouini, Hanieh Entezari, Hoda Lavasani, Yalda Hosseinzadeh Ardakani   +4 more
doaj   +1 more source

Characterization of Depressive and Anxiety Symptoms in Idiopathic REM Sleep Behavior Disorder

Journal of Parkinson’s Disease, 2021
Background: Depression and anxiety are common in synucleinopathies and often present during prodromal stages, including idiopathic/isolated REM sleep behavior disorder (iRBD).
Lucy Honeycutt, Jean-François Gagnon, Amélie Pelletier, Jacques Y. Montplaisir, Geneviève Gagnon, Ronald B. Postuma   +5 more
doaj   +1 more source

REM Sleep Behaviour Disorder in Multiple System Atrophy: From Prodromal to Progression of Disease

Frontiers in Neurology, 2021
A higher frequency of motor and breathing sleep-related disorders in multiple system atrophy (MSA) populations is reported. REM sleep behaviour disorder (RBD) is one of the most robust markers of an underlying alpha-synucleinopathy.
Giulia Giannini, Giulia Giannini, Federica Provini, Federica Provini, Pietro Cortelli, Pietro Cortelli, Giovanna Calandra-Buonaura, Giovanna Calandra-Buonaura   +7 more
doaj   +1 more source

Phenoconversion: Drug-Drug-Gene Interactions [PDF]

, 2019
Based on the extensive, poor, intermediate and ultrarapid phenotypes of patients, inferences may be made relative to drug metabolism, ultimately leading to changes in therapeutic drug choice or dosing.
Kulp, Molly, Kisor, David F., Marlowe, Brooke, Roberson, Taylor, Limberg, Emily   +4 more
core   +1 more source

Validation of the REM behaviour disorder phenoconversion-related pattern in an independent cohort [PDF]

, 2023
Background A brain glucose metabolism pattern related to phenoconversion in patients with idiopathic/isolated REM sleep behaviour disorder (iRBDconvRP) was recently identified.
Liguori C., Pardini M., Kim H., Arnaldi D., Mattioli P., García D. V., Donniaquio A., Meles S. K., Massa F., Nobili F., Bauckneht M., Orso B., Yoon E. J., Shin J. H., Famà F., Morbelli S., Chiaravalloti A., Kim Y. K., Kim R., Leenders K. L., Lee J. Y.   +20 more
core   +2 more sources

Table_1_Quantifying the Impact of Phenoconversion on Medications With Actionable Pharmacogenomic Guideline Recommendations in an Acute Aged Persons Mental Health Setting.DOCX

, 2021
Introduction: Polypharmacy and genetic variants that strongly influence medication response (pharmacogenomics, PGx) are two well-described risk factors for adverse drug reactions.
Carl M. J. Kirkpatrick (11294292), David Huppert (11294289), Thomas M. Polasek (11294283), Sam Mostafa (11294280), Leslie J. Sheffield (11294286)   +4 more
core   +1 more source

SerpinA3 is an Endogenous TGF‐β Receptor Antagonist that Attenuates Cardiac Fibroblast Activation and Fibrotic Remodeling

Advanced Science, EarlyView.
SerpinA3 acts as an endogenous TGF‐β receptor antagonist that binds to the extracellular domain of TGFR‐1, thereby preventing TGFR‐1–TGFR‐2 complex formation. This receptor‐level blockade suppresses TGF‐β/Smad2/3 signaling, attenuates cardiac fibroblast activation, and extracellular matrix deposition, and ultimately alleviates pressure overload–induced
Hui Wang, Jieyu Cui, Chunlu Huang, Wanyi Guo, Tong Liu, Yi Zhu, Shuai Shao, Kangyin Chen, Jinlong He, Qiankun Bao   +9 more
wiley   +1 more source